NovaBay Pharmaceuticals, Inc. (NYSE: NBY) is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. NovaBay has two distinct product categories: the NEUTROX family of products, led by AVENOVA for the eye care market, NEUTROPHASE for wound care and CELLERX for the dermatology market; and AGANOCIDE compounds, led by AURICLOSENE. For more information, visit the company’s website atwww.novabaypharma.com.